Naltrexone vs placebo for the treatment of alcohol dependence: a randomized clinical trial
DW Oslin, SH Leong, KG Lynch, W Berrettini… - JAMA …, 2015 - jamanetwork.com
Importance Alcohol use disorder is one of the leading causes of disability worldwide. While
effective pharmacological treatments exist, they are efficacious only in certain individuals,
contributing to their limited use. Secondary analysis of clinical trial data suggests that a
functional polymorphism (rs1799971, Asn40Asp) of the µ-opioid receptor gene (OPRM1) is
associated with the risk of relapse to heavy drinking following treatment with the opioid
antagonist naltrexone. Objective To prospectively examine whether rs1799971 is predictive …
effective pharmacological treatments exist, they are efficacious only in certain individuals,
contributing to their limited use. Secondary analysis of clinical trial data suggests that a
functional polymorphism (rs1799971, Asn40Asp) of the µ-opioid receptor gene (OPRM1) is
associated with the risk of relapse to heavy drinking following treatment with the opioid
antagonist naltrexone. Objective To prospectively examine whether rs1799971 is predictive …